TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Study of Hydrocortisone and Fludrocortisone in Glucocorticoid Insufficiency Related to Traumatic Brain Injury
Brief Summary: Traumatic brained injured (TBI) patients frequently suffered from glucocorticoid insufficiency that is associated with a raise in the rate of pneumonia.

In a placebo-controlled, multi-center, double-blinded trial, treatment of glucocorticoid insufficiency (hydrocortisone associated with fludrocortisone) will be assessed for prevention of post trauma pneumonia in a population of severe TBI patients.


Options:
A: Arm Label: Hydrocortisone and fludrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone Fludrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Controlled; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone Fludrocortisone; Assigned to Arm(s): Hydrocortisone and fludrocortisone
B: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Vitamin D Supplementation on Endothelial Function, Inflammation and Insulin Resistance in HIV
Brief Summary: The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebos | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Other: Placebos | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Other: Placebos | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Fenofibrate, Other: Placebos | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Drug: Fenofibrate | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): 3, 5 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 4, 5 | Intervention Type: OTHER; Name: Placebos; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: Selenium; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Selenium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Selenium; Assigned to Arm(s): Selenium | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vitamin D 4000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Vitamin D 4000 IU | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Third Prospective, Observational, International, Multicenter Study on Mechanical Ventilation
Brief Summary: The objective of this study is to obtain a better understanding of the spectrum of use of mechanical ventilation in intensive care units:

1. Main analysis: To know the all-cause mortality rate in mechanically ventilated patients
2. Secondary analyses:

   * To know the current status of mechanical ventilation in the intensive care unit and determine the number and percentage of patients who are admitted to an intensive care unit and require mechanical ventilation.
   * To compare the results with prior data collected in previous observational studies (1998 and 2004)
   * Non-invasive positive pressure ventilation
   * Weaning
   * Use of adjuvant therapies as steroids or selective digestive decontamination
   * Sedation including prevalence of delirium in mechanically ventilated patients
   * Prediction of the duration of mechanical ventilation
   * Other


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Smartcare/PS | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Smartcare/PS; Assigned to Arm(s): 1
B: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI
C: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
D: Arm Label: mechanically ventilated patients; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized Trial on the Effectiveness of Mindfulness Training for Smokers, a Novel Intervention Designed to Help Smokers Quit Smoking
Brief Summary: The Mindfulness Training for Smokers study follows a randomized controlled design with 240 total participants. Both the study group and the control group will be enrolled in the Wisconsin Tobacco Quit Line and will receive four weeks of nicotine patches. The control group will receive the Quit Line intervention alone where as the study group will receive the Quit Line intervention plus the Mindfulness for Smokers Intervention. The Mindfulness for Smokers Intervention provides four weeks of instruction in mindfulness meditation followed by four weeks of participation in a weekly meditation group. The principal hypothesis for the study is that Mindfulness for Smokers plus the Quit Line will lead to significantly higher rates of smoking cessation at 6 months than the Quit Line alone.


Options:
A: Arm Label: Mental Training for Surgeons; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Stress Reduction - modified | Arm Label: The Mind of a Surgeon; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active listening and reading | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction - modified; Assigned to Arm(s): Mental Training for Surgeons | Intervention Type: BEHAVIORAL; Name: Active listening and reading; Assigned to Arm(s): The Mind of a Surgeon
B: Arm Label: Mindfulness Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Training for Smokers | Arm Label: Integrated Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Integrated Training for Smokers | Arm Label: Quitline; Type: OTHER; Interventions: Behavioral: Quitline | Intervention Type: BEHAVIORAL; Name: Integrated Training for Smokers; Assigned to Arm(s): Integrated Training for Smokers | Intervention Type: BEHAVIORAL; Name: Mindfulness Training for Smokers; Assigned to Arm(s): Mindfulness Training for Smokers | Intervention Type: BEHAVIORAL; Name: Quitline; Assigned to Arm(s): Quitline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: yoga, Behavioral: cognitive therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive therapy, Behavioral: wellness | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: cognitive therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: wellness; Assigned to Arm(s): 2
D: Arm Label: Quit Line Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quit Line Only | Arm Label: Quit Line plus MTS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quit Line plus MTS | Intervention Type: BEHAVIORAL; Name: Quit Line plus MTS; Assigned to Arm(s): Quit Line plus MTS | Intervention Type: BEHAVIORAL; Name: Quit Line Only; Assigned to Arm(s): Quit Line Only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Partnerships to Overcome Obesity Disparities in Hawaii
Brief Summary: This is a 5-year community-based participatory research intervention study with the goals of 1) conducting a more definitive study of weight loss maintenance in Native Hawaiians and Pacific Peoples and 2) identifying the aspects of the community-academic partnership that fosters a co-learning and co-equal environment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Intervention Type: BEHAVIORAL; Name: Breaking Down Barriers; Assigned to Arm(s): 1, 2, 3
B: Arm Label: telecoaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telecoaching | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telecoaching; Assigned to Arm(s): telecoaching
C: Arm Label: self-guided weight loss maintenance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DVD group; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana 18-month weight loss maintenance | Arm Label: face-to-face group; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana 18-month weight loss maintenance | Intervention Type: BEHAVIORAL; Name: PILI 'Ohana 18-month weight loss maintenance; Assigned to Arm(s): DVD group, face-to-face group
D: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Brief Summary: Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated, expansive and irritable mood, often alternating with periods of significant clinical depression. People with Bipolar Disorder are typically heavy smokers who have difficulty quitting, and this is associated with significant tobacco-related medical illness and death.

The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder. This medication is the latest first-line pharmacotherapy for smoking cessation and has been shown to be efficacious for smoking cessation, but has not yet been systematically studied in persons with Bipolar Disorder.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Brief Summary: Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated, expansive and irritable mood, often alternating with periods of significant clinical depression. People with Bipolar Disorder are typically heavy smokers who have difficulty quitting, and this is associated with significant tobacco-related medical illness and death.

The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder. This medication is the latest first-line pharmacotherapy for smoking cessation and has been shown to be efficacious for smoking cessation, but has not yet been systematically studied in persons with Bipolar Disorder.


Options:
A: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Brief Summary: Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated, expansive and irritable mood, often alternating with periods of significant clinical depression. People with Bipolar Disorder are typically heavy smokers who have difficulty quitting, and this is associated with significant tobacco-related medical illness and death.

The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder. This medication is the latest first-line pharmacotherapy for smoking cessation and has been shown to be efficacious for smoking cessation, but has not yet been systematically studied in persons with Bipolar Disorder.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4
C: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Brief Summary: Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated, expansive and irritable mood, often alternating with periods of significant clinical depression. People with Bipolar Disorder are typically heavy smokers who have difficulty quitting, and this is associated with significant tobacco-related medical illness and death.

The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder. This medication is the latest first-line pharmacotherapy for smoking cessation and has been shown to be efficacious for smoking cessation, but has not yet been systematically studied in persons with Bipolar Disorder.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Brief Summary: Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated, expansive and irritable mood, often alternating with periods of significant clinical depression. People with Bipolar Disorder are typically heavy smokers who have difficulty quitting, and this is associated with significant tobacco-related medical illness and death.

The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder. This medication is the latest first-line pharmacotherapy for smoking cessation and has been shown to be efficacious for smoking cessation, but has not yet been systematically studied in persons with Bipolar Disorder.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Experimental Condition; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Placebo Condition; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Patch, Drug: Placebos | Arm Label: Quit condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Experimental Condition, Placebo Condition, Quit condition | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo Condition
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo

Answer: B